Workers’ Comp Drug Costs Reverse Course, Rising Sharply Across Most States

After years of decline, prescription payments per medical claim increased in the majority of states studied between 2022 and 2025, according to the Workers Compensation Research Institute.
By: | May 27, 2026
prescription drugs

Prescription drug costs in workers’ compensation systems have entered a new upward cycle, erasing much of the progress made during a prolonged period of cost reduction. At the median of 31 study states, quarterly prescription payments per medical claim rose 24% between the first quarter of 2022 and the first quarter of 2025 — climbing from $51 to $63 — after falling from $67 in early 2018, according to a Workers Compensation Research Institute report.

Topical Drugs and NSAIDs Remain the Dominant Cost Drivers

Dermatological agents — primarily topical analgesics applied directly to the skin — remained the single largest drug cost category, accounting for 23% of prescription payments in the median state as of the first quarter of 2025. In 12 of the 31 states studied, that share exceeded 30%, reaching 56% in Pennsylvania, 51% in Connecticut and 48% in Louisiana.

Nontraditional dispensing channels play a central role in driving these costs. In 20 of the 31 states, physician dispensing and delivery pharmacies — defined as pharmacies that ship or deliver medications directly to injured workers — together accounted for more than 70% of dermatological payments. In states with the highest dermatological payment shares, those channels represented roughly 80% to 95% of such spending, the report said.

Nonsteroidal anti-inflammatory drugs (NSAID) ranked second, accounting for 15% of payments in the typical state, though the range across states ran from 7% to more than 30%. Per-claim NSAID costs grew substantially in several states, driven in part by a shift toward higher-priced formulations. In New York, for example, diclofenac potassium 25 mg tablets — rarely dispensed elsewhere — accounted for 74% of NSAID payments in the first quarter of 2025.

Migraine Drugs Emerge as a Growing Expense

For the first time, the report tracked migraine drugs as a separate category, and the findings signal a fast-moving cost trend. By the first quarter of 2025, migraine drugs accounted for 10% to 26% of prescription payments in the states above the 75th percentile, compared with just 1% to 3% in the 11 lowest-share states. The increases were largely driven by the adoption of newer calcitonin gene-related peptide therapies, which carry higher price tags than traditional migraine treatments such as sumatriptan.

The largest payment share increases between 2022 and 2025 were recorded in Massachusetts (up 19 percentage points), Iowa and Kansas (each up 15 points) and Nevada (up 11 points).

Wide Interstate Variation Persists, With Policy Shaping Outcomes

The gap between high- and low-cost states remains striking. In the first quarter of 2025, quarterly prescription payments per medical claim ranged from roughly $14 in Minnesota to $353 in Louisiana — a 25-fold difference. Per-claim payments for workers with at least one prescription ranged from $93 in California to $1,291 in Louisiana.

Several states saw notable cost reductions tied directly to policy changes. In Georgia, a fee schedule update effective April 2024 capped reimbursements for topical medications, and dermatological payment shares dropped from a peak of 55% in early 2024 to 17% by the first quarter of 2025. South Carolina implemented similar limits in 2022 and saw comparable declines.

In contrast, New York recorded a 66% jump in per-claim payments — the largest of any state — coinciding with increased dispensing of higher-priced topical products designated as formulary drugs not requiring prior authorization, dispensed primarily by pharmacies in New York City.

Opioids continued their long-term decline, representing only about 3% of payments in the median state, with per-claim opioid payments falling in nearly all states — though at a slower pace than in earlier years. Physician-dispensing shares declined by 3 to 13 percentage points in 16 of the 31 study states between 2022 and 2025. Delivery pharmacies grew in importance across many states over the same period. In Pennsylvania, delivery pharmacies accounted for more than 70% of prescription payments and charged an average of $653 per prescription, compared with $136 at traditional retail pharmacies.

Obtain the full report here. &

The R&I Editorial Team can be reached at [email protected].

More from Risk & Insurance